A paper published in the prestigious scientific journal Nature involving the participation of IMOMA, has achieved significant breakthroughs in understanding the processes that lead to metastasis.
The important insurance company MAPFRE Familiar de Seguros y Reaseguros, S.A. and IMOMA have recently reached an agreement for the provision of radiotherapy treatment for all their health insurance policyholders
During the last months, specialists from IMOMA have taken part in SEOR, SECOM and semFYC national congresses, sharing their work developed in different areas of significance at the institution
The prestigious health insurance company Asistencia Sanitaria Interprovincial, S.A. (ASISA) and IMOMA have recently reached an agreement for the provision of radiotherapy treatment for all their private health insurance policyholders
The Institute of Molecular and Oncological Medicine of Asturias (IMOMA) has collaborated with an international scientific team which has succeeded in identifying new genes involved in pancreatic cancer
The Radiological Society of North America will celebrate its Annual Meeting next month in Chicago #RSNA 2014. On this occasion, the Department of Radiation Oncology at IMOMA and the Nuclear Medicine and Radiology Units at Centro Médico de Asturias, will be giving a presentation on radiotherapy treatment of skull base and paranasal tumors.
Head of the Radiophysics Unit, Dr. Manuel Vilches Pacheco, attended the prize giving ceremony to the blog Desayuno con Fotones (Breakfast with photons)
The project is supported by FICYT funding
We take great pleasure in informing all visitors that our site is now available in English:
Through their Spanish branch, the prestigious health insurer CIGNA Insurance Company of Europe, S.A.N.V. and IMOMA recently signed a service delivery agreement whereby all CIGNA policyholders may benefit from the leading-edge radiotherapy treatments available at IMOMA.
The mutations detected in the PMS2 gene cause Lynch syndrome: an inherited genetic condition that has a high risk to develop colon, rectal and endometrial cancers.
The study has been published in the prestigious "Journal of Medical Genetics"
The external independent audit EqualDose from the European Society for Therapeutic Radiation and Oncology (ESTRO). has been performed out on the radiotherapy planning and treatment delivery systems, at our Medical Physics and Radiation Protection Service.
Due to this collaboration, IMOMA now boasts high precision dosimetry instruments, in line with the innovative characteristics of the TrueBeam STx Linear accelerator
The IEF magazine recognises IMOMA's pioneering initiative in the fight against cancer.
(Disease, REsearch And Medicine) aims at advancing the practical application of genome research by transferring this information to medical diagnosis.
Doctors Lee, Shin and Lovelock visit the IMOMA's Radiotherapy facilities to contribute their knowledge and experience to the new service which will be up and running this autumn.